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Abstract 
Dysfunctional variants of the innate immune cell surface receptor TREM2 (triggering receptor 
expressed on myeloid cells-2) were identified as major genetic risk factors for Alzheimer’s 
disease and other neurodegenerative conditions. Here we assessed a possible involvement 
of TREM2 in prion disease. We report that TREM2 expression by microglia is significantly 
upregulated upon prion infection. However, depletion of TREM2 did not affect disease 
incubation time and survival after intracerebral prion infection. Interestingly, markers of 
microglial activation were attenuated in prion-infected TREM2-/- mice, suggesting an 
involvement of TREM2 in prion-induced microglial activation. Further phenotype profiling of 
microglia revealed that TREM2 deficiency did not change microglial phenotypes. We 
conclude that TREM2 is involved in prion-induced microglial activation, but does not 
noticeably modulate the pathogenesis of experimental prion infections.  
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1 Introduction 
Prion diseases are fatal neurodegenerative disorders, which include scrapie in sheep and 
goats, bovine spongiform encephalopathy in cows, as well as Creutzfeldt-Jakob disease 
(CJD) and kuru in humans (Aguzzi, et al., 2013). Prion diseases are, to date, incurable. The 
histopathological features of prion diseases encompass neuronal loss, gliosis, spongiform 
changes and the deposition of PrPSc, an abnormal isoform of the cellular prion protein (PrPC) 
encoded by the Prnp gene. A crucial feature that distinguishes prion diseases from all other 
neurodegenerative diseases is transmissibility between individuals. The infectious agent is 
composed of PrPSc, which can act as template to induce the conversion of PrPC into 
infectious stereoisoforms (Prusiner, 1982). Therefore, elimination of PrPC abolishes the 
conversion of PrPC into PrPSc, and Prnp-/- mice are resistant to prion infections.  
Pulse-chase studies of prion infectivity in Prnp-ablated mice, which lack all PrPC, have shown 
that prions can be cleared in vivo with surprising efficiency (Sailer, et al., 1994). It was then 
found that microglia, the most prevalent immune cells of the brain, act as the main scavenger 
of prions. In prion-infected cerebellar organotypic cultured slices, depletion of microglia vastly 
enhances prion deposition and leads to increased prion infectivity (Falsig, et al., 2008). The 
opsonin Mfge8 is instrumental for microglia-dependent clearance of prions, possibly by 
bridging phospholipids trapped within PrPSc to integrins expressed by microglia (Kranich, et 
al., 2010). However, the impact of Mfge8 is highly variable among different mouse strains, 
suggesting that additional molecules (which may be polymorphic in the mouse) play roles 
similar to Mfge8 in prion clearance (Aguzzi and Zhu, 2012). The identification of such 
additional molecules is of practical importance, since they may represent therapeutic targets 
for this group of diseases.  
Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune cell surface 
receptor that facilitates phagocytosis of apoptotic neurons and bacteria, thereby quenching 
inflammation (N'Diaye, et al., 2009,Takahashi, et al., 2005). Loss-of-function mutations in 
TREM2 occur in patients suffering from Nasu-Hakola disease, which is characterized by 
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bone cysts and early-onset progressive dementia (Paloneva, et al., 2002). These findings 
have prompted studies of TREM2 in other neurodegenerative conditions such as Alzheimer’s 
disease (AD). TREM2 has been reported to be upregulated in mouse models of AD (Frank, 
et al., 2008), and – crucially – two independent studies have found that variants of TREM2 
are associated with a higher risk of developing AD (R. Guerreiro, et al., 2013b,Jonsson, et al., 
2013). These findings have spurred numerous studies addressing the association between 
TREM2 and AD and other neurodegenerative diseases. Although negatives have been 
reported (Jiao, et al., 2014,Ma, et al., 2014,Miyashita, et al., 2014,Ruiz, et al., 2014,Yu, et al., 
2014), the association between TREM2 variants and AD has been confirmed by most studies 
(Benitez, et al., 2013,Cuyvers, et al., 2014,Giraldo, et al., 2013,Gonzalez Murcia, et al., 
2013,Luis, et al., 2014,Slattery, et al., 2014). Moreover, TREM2 variants were also found to 
be associated with frontotemporal dementia-like syndrome or FTD (Borroni, et al., 2014,R. 
Guerreiro, et al., 2013a,R.J. Guerreiro, et al., 2013,Le Ber, et al., 2014,Rayaprolu, et al., 
2013,Thelen, et al., 2014), Parkinson’s disease (PD) (Rayaprolu, et al., 2013), and sporadic 
amyotrophic lateral sclerosis (ALS) (Cady, et al., 2014). These findings raise the question 
whether the dysregulation of crucial immunological functions associated with TREM2 
variants may be a general causative factor in a broad spectrum of neurodegenerative 
diseases.  
TREM2 has been reported to function as a phagocytic receptor for neuronal debris and 
bacteria (N'Diaye, et al., 2009,Takahashi, et al., 2005). Therefore, it is conceivable that 
TREM2 may also facilitate the phagocytosis and clearance of extracellularly deposited 
protein aggregates, such as Aβ plaques. Therefore, loss-of-function mutations in TREM2 
may lead to unimpeded protein aggregate deposition and result in progression of the 
respective diseases. Indeed, missense TREM2 mutations associated with FTD and FTD-like 
syndrome were found to reduce TREM2 protein maturation, thereby abolishing its shedding 
by ADAM proteases and impairing the phagocytic activity of TREM2-expressing cells 
(Kleinberger, et al., 2014). However, others reported that the depletion of one allele of 
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TREM2 in the APPPS1 mouse model did not affect Aβ deposition, even if TREM2 
heterozygosity altered the microglial response in these mice (Ulrich, et al., 2014). Therefore, 
it remains unknown if, and to what extent, complete depletion of TREM2 affects Aβ 
catabolism. Interestingly, overexpression of TREM2 in a mouse model of AD afforded 
protection against AD progression through the modulation of microglia functions (Jiang, et al., 
2014a). 
Here we searched for a possible role of TREM2 in a mouse model of prion disease. We 
found that TREM2 expression in microglia was significantly upregulated by prion infection, 
and microglial activation was significantly attenuated in prion-infected TREM2-/- mice. 
However, ablation of TREM2  did not change the incubation time and the salient biochemical 
and pathophysiological features after intracerebral inoculation of prions. Our study suggests 
that TREM2 is involved in prion-induced microglial activation, but does not contribute to prion 
pathogenesis in the mouse brain. 
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2 Material and methods 
2.1 Ethical statement 
All animal experiments were carried out in strict accordance with the Rules and Regulations 
for the Protection of Animal Rights (Tierschutzgesetz and Tierschutzverordnung) of the 
Swiss Bundesamt für Veterinärwesen and were preemptively approved by the Animal 
Welfare Committee of the Canton of Zürich (permit # 41/2012). 
 
2.2 Animals 
TREM2−/− mice carrying a targeted deletion of exon 3 and 4, which encodes portions of 
transmembrane and cytoplasmic domains of TREM2 (Turnbull, et al., 2006) were first 
backcrossed to C57BL/6J to obtain TREM2+/- offspring. TREM2+/- mice were then 
intercrossed to obtain TREM2-/-, TREM2+/- and TREM2+/+ (WT) littermates, which were used 
for the experiments described here. For microglia depletion experiments, we used 
Tg20/CD11b-HSVTK mice (Heppner, et al., 2005). 
 
2.3 Prion inoculation 
Mice were intracerebrally (i.c) inoculated with 30 μl of brain homogenate diluted in PBS with 
5% BSA and containing 3 x 5 log LD50 units of the Rocky Mountain Laboratories scrapie 
strain (passage 6, thus called RML6). Scrapie was diagnosed according to clinical criteria 
(ataxia, kyphosis, priapism, and hind leg paresis). Mice were sacrificed on the day of onset of 
terminal clinical signs of scrapie. 
 
2.4 Organotypic slice cultures and microglia depletion.  
Cerebellar organotypic slices were prepared from 9-11-day old pups and maintained 
according to previously published protocols (Falsig, et al., 2008). In Tg20/CD11b-HSVTK 
brain slices, microglia were depleted by adding ganciclovir from 0 to 21 days in vitro. Slices 
were then infected with 10-4 dilution of RML6 prions or non-infectious brain homogenates 
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from CD1 mice (NBH). Five weeks postinoculation, slices were harvested and total RNA was 
extracted.  
 
2.5 Quantitative real-time PCR (qRT-PCR) 
Total RNA from brain or cultured slices was extracted using TRIzol (Invitrogen) according to 
the manufacturer’s instruction. The quality of RNA was analyzed by Bioanalyzer 2100 
(Agilent Technologies), RNAs with RIN>6 were used for cDNA synthesis. cDNA were 
synthesized from ~1 µg total RNA using QuantiTect Reverse Transcription kit (QIAGEN) 
according to the manufacturer’s instruction. Quantitative real-time PCR (qRT-PCR) was 
performed using the SYBR Green PCR Master Mix (Roche) on a ViiA7 Real-Time PCR 
system (Applied Biosystems). Expression levels were normalized using GAPDH. The 
sequence of qRT-PCR primers are in table 1. 
 
2.6 Western blot analysis 
To detect PrPC in the TREM2-/-, TREM2+/- and TREM2+/+ (WT) brains, hemisphere of brains 
were homogenized with buffer PBS containing 0.5% Nonidet P-40 and 0.5%CHAPSO. Total 
protein concentration was determined using the bicinchoninic acid assay (Pierce). ~8 µg 
proteins were loaded and separated on a 12% Bis-Tris polyacrylamide gel (NuPAGE, 
Invitrogen) and then blotted onto a nitrocellulose membrane. Membranes were blocked with 
5% wt/vol Topblock (Fluka) in PBS supplemented with 0.05% Tween 20 (vol/vol) and 
incubated with primary antibodies POM1 in 1% Topblock (200 ng ml−1) overnight. After 
washing, the membranes were then incubated with secondary antibody horseradish 
peroxidase (HRP)-conjugated rabbit anti–mouse IgG1 (1:10,000, Zymed). Blots were 
developed using Luminata Crescendo Western HRP substrate (Millipore) and visualized 
using the Stella system (model 3000, Bio-Rad). To avoid the variation in loading, the same 
blots were striped and incubated with an anti-actin antibody (1:10,000, Millipore). The PrPC 
signals were normalized to actin as a loading control. 
8 | P a g e  
 
To detect PrPSc, prion infected forebrains were homogenized in sterile 0.32 M sucrose in 
PBS. Total protein concentration was determined using the bicinchoninic acid assay (Pierce). 
Samples were adjusted to 20 µg protein in 20 µl and digested with 25 µg ml−1 proteinase K in 
digestion buffer (PBS containing 0.5% wt/vol sodium deoxycholate and 0.5% vol/vol Nonidet 
P-40) for 30 min at 37°C. PK digestion was stopped by adding loading buffer (Invitrogen) and 
boiling samples at 95°C for 5 min. Proteins were then separated on a 12% Bis-Tris 
polyacrylamide gel (NuPAGE, Invitrogen) and blotted onto a nitrocellulose membrane. POM1 
and horseradish peroxidase (HRP)-conjugated rabbit anti–mouse IgG1 were used as primary 
and secondary antibodies, respectively. Blots were developed using Luminata Crescendo 
Western HRP substrate (Millipore) and visualized using the FUJIFILM LAS-3000 system. To 
detect IBA-1 and GFAP in prion-infected brains by western blotting, 20 µg of total brain 
protein were loaded and anti-IBA-1 antibody (1:1000; Wako Chemicals GmbH, Germany) 
and anti-GFAP antibody (1:10,000; Abcam) were used. Actin was used as loading control. 
 
2.7 Immunohistochemistry 
Formalin-fixed tissues were treated with concentrated formic acid for 60 min to inactivate 
prion infectivity and embedded in paraffin. Paraffin sections (2 μm) of brains were stained 
with hematoxylin/eosin (HE). After deparaffinization through graded alcohols, antibodies 
GFAP (1:300; DAKO, Carpinteria, CA) for astrocytes were applied and visualized using 
standard methods, IBA-1 (1:1000; Wako Chemicals GmbH, Germany) was used for 
highlighting activated microglial cells. Stainings were visualized using DAB (Sigma-Aldrich), 
hematoxylin counterstain was subsequently applied. For the histological detection of partially 
proteinase K-resistant prion protein deposition, deparaffinized sections were pretreated with 
formaldehyde for 30min and with 98% formic acid for 6 min, and then washed in distilled 
water for 30 min. Sections were incubated in Ventana buffer and stains were performed on a 
NEXEX immunohistochemistry robot (Ventana instruments, Switzerland) using an IVIEW 
DAB Detection Kit (Ventana). After incubation with protease 1 (Ventana) for 16 min, sections 
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were incubated with anti-PrP SAF-84 (SPI bio, A03208, 1:200) for 32 min. Sections were 
counterstained with hematoxylin. Sections were imaged using a Zeiss Axiophot light 
microscope. Quantification of IBA-1 and GFAP staining was performed on acquired images; 
regions of interest were drawn and the percentage of brown IBA-1 and GFAP staining over 
the total area was quantified using scripts developed in-house. The operator was blind to the 
genotype and treatment of the analyzed tissues.  
 
2.8 Statistical analysis 
Results are presented as the mean of replicas ± standard deviation (SD). Statistical 
significance between experimental groups was assessed using an unpaired Student’s t-Test. 
Incubation times were analyzed using the Kaplan-Meier method and compared to gender-
matched TREM2+/+ (WT) littermates using the logrank test. p-values <0.05 were considered 
statistically significant. 
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3 Results 
3.1 Prion infection upregulates TREM2 and DAP12 expression by microglia in mouse brain 
TREM2 has been described to be upregulated in AD mouse models (Frank, et al., 2008). To 
determine whether TREM2 expression is altered by prion infection, we carried out 
quantitative reverse-transcription PCR (qRT-PCR) on mRNA isolated from terminally sick 
wild-type (WT) C57BL/6 mice infected with the Rocky Mountain Laboratory strain of mouse-
adapted scrapie prions (passage #6, inoculum hence nicknamed RML6), age-matched WT 
C57BL/6 mice inoculated with non-infectious brain homogenates (NBH), and Prnp-/- mice 
infected with RML6. We found TREM2 mRNA to be significantly upregulated (6.5-fold) in 
RML6-infected C57BL/6 mice compared to NBH-inoculated controls (Figure 1A). Prion-
resistant Prnp-/- mice (Bueler, et al., 1993) inoculated with RML6 did not show any 
upregulation of TREM2 expression (Figure 1A), which is in accordance with the absence of 
prion pathology in those mice. Therefore, similarly to what was reported for AD mouse 
models, TREM2 is upregulated in a mouse model of prion diseases. Interestingly, the 
adapter protein DAP12 that is associated with TREM2 was also significantly upregulated 
(6.1-fold) in prion infected brains (Figure 1A). 
Myeloid cells are the main sources of TREM2, and microglia are thought to be the main 
producers of TREM2 within the brain (Jiang, et al., 2014b). To assess the contribution of 
microglia to the expression of TREM2 in the brain after prion infection, we prepared 
cerebellar organotypic cultured slices (COCS) from transgenic mice that express the herpes 
simplex virus thymidine kinase under the promoter of CD11b and overexpress PrPC 
(Tg20/CD11b-HSVTK). Treatment of such COCS with ganciclovir (GCV) essentially removes 
all microglia (Heppner, et al., 2005).  
After prion infection, microglia-containing slices expressed significantly more TREM2 (2.5-
fold) than NBH-exposed slices, similarly to what we had observed in vivo. However, after 
microglia depletion, TREM2 was barely detectable in both RML and NBH treated slices 
(Figure 1B). Similarly, DAP12 was also significantly upregulated (2.3-fold) in prion infected 
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microglia-containing slices and was barely detectable when microglia were depleted (Figure 
1B). The small amounts of TREM2 and DAP12 remaining in microglia-depleted samples 
(<0.1% of NBH) originated from residual microglia, since several other microglial markers 
(CD11b, CSF1R, CX3CR1) showed similar expression pattern as TREM2 and DAP12 in 
microglia-depleted slices (Figure 1C). Collectively, these results indicate that microglia are 
not only the main cell type expressing TREM2 and DAP12 in the brain under physiological 
conditions, but they are also the dominant cell type that is induced to express TREM2 and 
DAP12 after prion infection. 
 
3.2 TREM2 deficiency does not affect PrPC expression  
The expression level of PrPC is the primary factor influencing prion incubation time. 
Reduction of PrPC by 50% (in Prnp+/- hemizygous mice) drastically prolongs the incubation 
time of prion disease (Bueler, et al., 1993), whereas overexpression of PrPC markedly 
shortens prion disease progression (Fischer, et al., 1996). To evaluate whether TREM2 
deficiency could affect PrPC expression, we first measured Prnp mRNA levels in the brains of 
TREM2-/-, TREM2+/- and TREM2+/+ (WT) littermates by qRT-PCR. We did not observe any 
significant differences in Prnp mRNA between these three groups (Figure 2A). As expected, 
TREM2 mRNA was about 50% in TREM2+/- mice compared to TREM2+/+ mice, and 
undetectable in TREM2-/- mice (Figure 2A). We also assessed the PrPC protein content of 
brains from TREM2-/-, TREM2+/- and TREM2+/+ (WT) littermates by western blot, and found 
that all three groups of mice expressed similar levels of PrPC (Figure 2B). Hence TREM2 
deficiency does not affect PrPC expression in mouse brain. 
 
3.3 Similar prion pathogenesis in TREM2-/- and wild-type littermates after intracerebral 
inoculation 
To determine if TREM2 is involved in prion pathogenesis in the brain, we inoculated RML6 
intracerebrally into TREM2-/-, TREM2+/- and TREM2+/+ (WT) littermates. The incubation time 
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was determined by measuring the time lapse between inoculation and the terminal stage of 
prion disease. Since gender was reported to be a factor affecting prion incubation time 
(Akhtar, et al., 2011), we compared female and males with different genotypes separately. 
However, we observed similar incubation times in all three groups (Figure 3A) in both 
females and males.  
TREM2 is considered as an important receptor for phagocytosis, which is the main 
mechanism of prion elimination from the brain. In order to assess whether TREM2 is involved 
in prion clearance, we analyzed PrPSc deposition in terminally scrapie-sick mice. We did not 
observe any statistically significant differences in the total amount of proteinase K (PK) 
resistant prion protein (PrPSc) between TREM2+/+, TREM2+/-, and TREM2-/- brains (Figure 3B). 
Prion infectivity of terminally sick mouse brains was determined using a cell-based end-point 
dilution method, and showed similar prion titers in all three genotypes (Figure 3C). 
Histological examination of the brains at the terminal stage of disease revealed similar lesion 
patterns, with equivalent PrPSc deposit levels (Figure 3B and 3D) and astrogliosis in the three 
groups (Figure 3D, 3E and 3F). Therefore, although prion infection induced upregulation of 
TREM2 expression by microglia, TREM2 did not exert a discernible impact onto various 
parameters of prion disease pathogenesis. 
 
3.4 TREM2-/- mice displayed attenuated microglial activation upon prion infection 
TREM2 has been found to facilitate the phagocytosis of apoptotic neurons and to suppress 
inflammatory responses (Takahashi, et al., 2005). To determine whether depletion of TREM2 
affects the basal inflammatory levels in the brain, we first measured the proinflammatory 
cytokines TNFα, IL-1β and IL-6 in the brains of TREM2-/-, TREM2+/- and TREM2+/+ (WT) 
littermates by qRT-PCR. Interestingly, we did not detect significant differences between the 
groups (Figure 4A). Therefore, we conclude that TREM2 deficiency has a limited impact, if 
any, on the baseline inflammatory status of mouse brains. We also analyzed the expression 
of proinflammatory cytokines TNFα, IL-1β and IL-6 in the brains of prion-infected TREM2-/-, 
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TREM2+/- and TREM2+/+ (WT) littermates. Consistently with previous studies, these cytokines 
were all upregulated upon prion infection (Figure 4A). However, ablation of TREM2 did not 
significantly alter the expression of these cytokines (Figure 4A). 
Neuroinflammation including microglial activation is one of the hallmarks of prion 
pathogenesis, and it has been suggested that activated microglia may damage brain 
structures – thereby contributing to neurodegeneration. As suggested by previous 
publications and confirmed by our own experiments, TREM2 is mainly expressed by 
microglia in the brain. To test whether TREM2 deficiency affects prion-induced microglial 
activation, we assessed microglial activation in the brains of terminally sick mice by IBA-1 
immunohistochemical staining. Interestingly, we found significantly reduced microglial density 
in TREM2-/- mice compared to their TREM2+/+ (WT) littermates (Figure 4B), suggesting that 
proliferation of microglia in TREM2-/- mice was diminished. IBA-1 western blot of brain tissue 
from terminally sick mice confirmed that TREM2-/- mice showed less microglial activation 
(Figure 4C). We conclude that TREM2 does play a role in prion-dependent microglial 
activation, even if it does not control prion pathogenesis. 
Analogous to extracerebral macrophages, microglia can be polarized into two different 
phenotypes termed M1 and M2. M1-polarized microglia show pro-inflammatory features and 
express TNFα, IL-1β, IL-6, inducible nitric oxide synthase (iNOS), and arginase 2 (Arg2), 
whereas M2 microglia display a phagocytic behavior and express FIZZ1, Ym1/2 and 
arginase 1 (Arg1). To better characterize the role of TREM2 in prion induced microglial 
activation, we carried out qRT-PCR for genes reflecting the phenotype of microglia in 
TREM2-/-, TREM2+/- and TREM2+/+ (WT) mice infected with RML6 prions or exposed to non-
infectious brain homogenates, respectively. We did not observe any statistically significant 
differences between the three groups (Figure 4D). Therefore, TREM2 deficiency did not alter 
the baseline microglial polarization and did not change the prion-induced microglia 
neuroinflammatory phenotype.  
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4 Discussion 
Neuroinflammation has been discussed as a pathogenetic factor in neurodegeneration for 
many years, but it has been difficult to corroborate this concept. The finding that TREM2 
variants act as strong genetic risk factors for Alzheimer’s disease and many other 
neurodegenerative diseases (Benitez, et al., 2013,Borroni, et al., 2014,Cady, et al., 
2014,Cuyvers, et al., 2014,Giraldo, et al., 2013,Gonzalez Murcia, et al., 2013,R. Guerreiro, et 
al., 2013a,R. Guerreiro, et al., 2013b,R.J. Guerreiro, et al., 2013,Jonsson, et al., 2013,Le Ber, 
et al., 2014,Rayaprolu, et al., 2013) represents the most direct evidence to date that immune 
functions can modulate the course of these diseases. According to the currently prevailing 
view, loss-of-function mutations in TREM2 may result in unconstrained protein aggregate 
deposition and accelerate progression of these diseases.  
Because prion infections go along with conspicuous extracellular aggregates of PrPSc, it 
seemed worthwhile to test whether experimental prion diseases is affected by the TREM2 
state of the host. In contrast to most other models of neurodegeneration, prion-infected mice 
undergo a highly stereotypic course of disease with a well-defined incubation and survival 
time. These properties greatly facilitate the objective and precise assessments of the impact 
of genetic manipulations on prion pathogenesis. We opted to investigate the model of 
mouse-adapted scrapie, a prion disease which not only sports highly predictable and 
homogeneous incubation times but also robust endpoints and reliable biomarkers.  
Prion infections are among the most powerful stimuli for microglia proliferation, and indeed 
we found that TREM2 is conspicuously upregulated (6.5-fold) upon prion infection. This 
finding is consistent with reports that within the CNS, TREM2 is primarily expressed by 
microglia, but it may reflect correlation rather than causality. We therefore investigated this 
issue further by using the CD11b-HSVTK transgenic mice, which express the tyrosine kinase 
of Herpes simplex virus under the transcriptional control of the myeloid CD11b promoter. 
Exposure of CD11b-HSVTK organotypic cerebellar slices to ganciclovir results in its 
phosphorylation to a nucleoside analogue that poisons cells undergoing DNA synthesis 
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(including mitochondrial DNA). This results in rapid, selective and complete ablation of all 
microglia. These experiments provided more definitive proof that microglia are not only the 
main source of TREM2 expression in mouse brain, but also the dominant cell type that is 
stimulated to express TREM2 after prion infection. We noticed that the extent of TREM2 and 
DAP12 upregulation in Tg20/CD11b-HSVTK COCS was less abundant than in the in vivo 
brain samples. We ascribe this phenomenon to the process of COCS generation, which 
results in sizeable microglial activation by itself. Such pre-activated microglia may be unable 
to demonstrate a higher degree of activation upon additional stimuli. 
Although TREM2 expression was conspicuously upregulated by prion infection, its ablation 
did not alter the speed of prion disease progression. Moreover, PrPSc deposition and 
astrogliosis were similar in all three groups. Since the phagocytic activity of microglia is a 
well-established limiting factor for prion propagation within the brain(Falsig, et al., 
2008,Kranich, et al., 2010,Nuvolone, et al., 2013), the unchanged PrPSc deposition and prion 
infectivity titer suggested that the phagocytosis of prions by TREM2-/- microglia was not 
markedly affected. However, TREM2 seems to be involved in microglial activation, as the 
prion-induced enhancement of IBA-1 reactivity was attenuated in TREM2-/- mice. This is 
consistent with a previous report that APPPS1 mice heterozygous for TREM2 exhibited 
decreased number and size of plaque-associated microglia (Ulrich, et al., 2014). The latter 
data confirm that microglial activation was attenuated upon TREM2 hemizygosity, yet their 
phagocytic capacity was not obviously compromised. In a study on stroke model, microglial 
activity in the subacute phase was also reduced in TREM2-/- mice although the lesion size 
was not affected (Sieber, et al., 2013). Collectively, these results suggest that TREM2 is an 
important mediator for microglial activation. The absence of effect of TREM2 on Aβ plaques 
and prion load is surprising; it suggests that the microglial activation state may not 
necessarily correlate with their phagocytic capacity.  Together with our previous findings that 
depletion of microglia enhances prion replication in organotypic cerebellar slices (Falsig, et 
al., 2008), we hypothesize that the availability of microglia, and perhaps a basal level of 
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activation, may be crucial for phagocytosis, whereas further activation does not appear to 
augment the clearance of prions. Accordingly, lipopolysaccharide-stimulated microglial 
activation did not enhance further phagocytosis of prions (Hughes, et al., 2010). 
Further microglia profiling indicated that TREM2 did not conspicuously affect microglial 
polarization under physiological conditions and after prion infection. We did identify minor 
trends in some markers which may have arguably reached statistical significance if a larger 
collective of animals had been studied. Notwithstanding this caveat, our results suggest that 
the action of TREM2 on microglia is subtle and does not exert any immediately obvious 
impact onto its functionality. In particular, its effect onto the pathogenesis and course of prion 
infection is negligible. 
One possible limitation to our study is that we did not exclude the effect of TREM2 deficiency 
on peripheral macrophages that might invade the central nervous system (CNS) under 
pathological conditions. Although there is no evidence that TREM2 affects the recruitment of 
macrophages from the periphery to the CNS, this question remains open and may merit 
further investigations.  
Along with the failure to find any association between specific TREM2 allelotypes and 
sporadic CJD (Slattery, et al., 2014), the findings described here add to the evidence that 
TREM2 is not a major determinant of prion pathogenesis. This fact is unexpected and sets 
prions apart from other neurodegenerative diseases such AD, FTD, PD, and ALS.    
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Figure captions 
Figure 1: Upregulation of TREM2 and DAP12 after prion infection. (A) qRT-PCR for TREM2 
and DAP12 expression. Age-matched wild-type C57BL/6 mice were intracerebrally 
inoculated with prion-containing or non-infectious CD1 mouse brain homogenates (RML and 
NBH, respectively; days after inoculation: ~170). Prion-inoculated Prnp-/- mice served as 
additional controls. TREM2 and DAP12 mRNAs were significantly upregulated in prion-
infected WT mice, but not in prion resistant Prnp-/- mice (n=4, ***: p<0.001, ****: p<0.0001). 
(B) Cerebellar organotypic cultured slices from Tg20/CD11b-HSVTK mice were treated with 
ganciclovir (GCV) to deplete microglia. GCV-treated and untreated controls were infected 
with RML6 prions or NBH. In GCV-treated slices, TREM2 and DAP12 were barely detectable, 
indicating that TREM2 and DAP12 are mainly contributed by microglia. Without GCV, 
TREM2 and DAP12 expression was again upregulated upon prion infection (n=4, ** p<0.01, 
***: p<0.001, **** p<0.0001). (C) qRT-PCR for CD11b, CSF1R and CX3CR1 expression on 
Tg20/CD11b-HSVTK cerebellar organotypic cultured slices. Similarly to TREM2 and DAP12, 
these microglial markers were barely detectable in microglia-depleted slices, yet were 
upregulated in prion infected, microglia-containing slices (n=4, *: p<0.05, ** p<0.01, ***: 
p<0.001, **** p<0.0001). Data are presented as the mean ± SD. 
 
Figure 2: Unaltered PrPC expression in TREM2 deficient mice. (A) Prnp mRNA levels in 
TREM2+/+ (WT), TREM2+/- and TREM2-/- littermates were similar (n=3, n.s p>0.05). TREM2 
mRNA level was about half in TREM2+/- littermates (n=3, ** p<0.01) and undetectable in 
TREM2-/- littermates. (B) Western blot showing similar PrPC concentrations in brains of 
TREM2+/+ (WT), TREM2+/-, and TREM2-/- littermates (n=4, n.s p>0.05 Data are presented as 
mean ± SD. 
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Figure 3: Unaltered pathogenesis in TREM2-ablated mice after intracerebral prion infection. 
(A) Similar survival curves of gender-matched TREM2+/+, TREM2+/- and TREM2-/- littermates 
intracerebrally inoculated with RML6 prions (n=3-7, n.s: p>0.05). (B) Left: Western blot for 
proteinase K resistant PrPSc in terminally sick mouse brains. Right: densitometric 
quantification failed to reveal differences between TREM2+/+ (WT), TREM2+/- and 
TREM2-/- littermates (n=3, n.s: p>0.05). (C) Similar prion titers in terminally sick mouse brains 
from TREM2+/+ (WT), TREM2+/-, and TREM2-/- littermates (n=3, n.s: p>0.05). (D) 
Representative histology of terminally sick mouse brains from TREM2+/+ (WT), TREM2+/- and 
TREM2-/- littermates. There was no obvious difference between the three groups in lesion 
patterns, vacuolation, PrPSc deposition. Scale bars are 100μm. (E) Quantification of GFAP 
staining for terminally sick mouse brains from TREM2+/+ (WT), TREM2+/- and 
TREM2-/- littermates. There was no obvious difference between the three groups in 
astrogliosis (n=5~6, n.s: p>0.05). (F) Western blot of brains from terminally sick TREM2+/+ 
(WT), TREM2+/- and TREM2-/- littermates showed that GFAP expression was similar in 
TREM2+/+ (WT), TREM2+/- and TREM2-/- littermates (n=3, n.s: p>0.05). Data are presented 
as the mean ± SD. 
 
Figure 4: TREM2 deficiency attenuated microglial activation upon prion infection, but did not 
change the expression of inflammatory markers and the microglial phenotype. (A) The 
mRNA levels of the inflammatory cytokines, TNFα, IL-1β and IL-6, were upregulated upon 
prion infection, but were unaffected by TREM2 ablation (n=3, n.s: p>0.05). (B) 
Representative IBA-1 immunohistochemical staining on cortex and hippocampus of 
terminally sick mouse brains from TREM2+/+ (WT), TREM2+/- and TREM2-/- littermates. 
TREM2-/- mice had significantly less microglial activation than TREM2+/+ littermates (n=5~9, 
** p<0.01). Scale bars are 20μm. (C) Western blot of brains from terminally sick TREM2+/+ 
(WT), TREM2+/- and TREM2-/- littermates showed that IBA-1 expression was linearly 
dependent on TREM2 gene dosage (n=3, *: p<0.05). (D) TREM2 deficiency did not affect the 
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expression of pro-inflammatory M1 microglia markers (iNOS, Arg2) or anti-inflammatory M2 
microglia markers (FIZZ1, Ym1/2, Arg1) under both physiological condition or upon prion 
infection (n=3, n.s: p>0.05). Data are presented as the mean ± SD. 
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Table 1: qRT-PCR primers 
Gene Forward primer 5'-3' Reverse primer 5'-3' 
GAPDH CCACCCCAGCAAGGAGACT GAAATTGTGAGGGAGATGCT 
TREM2 GCACCTCCAGGAATCAAGAG GGGTCCAGTGAGGATCTGAA 
DAP12 TGCCTTCTGTTCCTTCCTGT GGGCATAGAGTGGGCTCAT 
CD11b GTGTGACTACAGCACAAGCCG CCCAAGGACATATTCACAGCCT 
CSF1R GCAGTACCACCATCCACTTGTA GTGAGACACTGTCCTTCAGTGC 
CX3CR1 ACCGGTACCTTGCCATCGT ACACCGTGCTGCACTGTCC 
Prnp GCCAGTGGATCAGTACAGCA ATCCCACGATCAGGAAGATG 
TNFα ACTTCGGGGTGATCGGTCCCC TGGTTTGCTACGACGTGGGCTAC 
IL-1β TGCAGCTGGAGAGTGTGGATCCC TGTGCTCTGCTTGTGAGGTGCTG 
IL-6 TCCAATGCTCTCCTAACAGATAAG CAAGATGAATTGGATGGTCTTG 
FIZZ1 AGGAACTTCTTGCCAATCCA CAGTAGCAGTCATCCCAGCA 
Arg1  CAGAAGAATGGAAGAGTCAG CAGATATGCAGGGAGTCACC 
Ym1/2  CAGGGTAATGAGTGGGTTGG CACGGCACCTCCTAAATTGT 
iNOS GTCATGGCTTCACGGGTCAG CCAGGTCCCTGGCTAGTGCT 
Arg2 TGATTGGCAAAAGGCAGAGG CTAGGAGTAGGAAGGTGGTC 
 




